Clinic Hospital Nuclear Medicine Radiopharmaceuticals 
AuntMinnie
MAY 8, 2024
Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. Extravasations Extravasations, in particular, are of interest to the U.S.
Imaging Technology
FEBRUARY 21, 2024
milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
JUNE 11, 2024
She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.
AuntMinnie
JUNE 11, 2024
TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Imaging Technology
JUNE 10, 2024
Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As
AuntMinnie
FEBRUARY 20, 2024
Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical. and its findings were published in December in the Journal of Nuclear Medicine. Blue Earth said.
Expert insights. Personalized for you.
75 
Let's personalize your content